Navigation Links
Immtech to Reorganize Research and Development Operations
Date:4/21/2009

NEW YORK, April 21 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (NYSE Amex: IMM) announced today that the Company is reorganizing its R&D operations. This restructuring will direct resources to business opportunities based on the Company's ongoing discovery program and library of proprietary compounds. With this change, the Company also announced that the position of Senior Vice President for Pharmaceutical Development & Chief Medical Officer is being eliminated. This position was held by Carol Ann Olson, M.D., Ph.D. She will continue to work with Immtech in a consulting role for pharmaceutical development.

"We thank Dr. Olson for her dedication and efforts and wish her well in her future endeavors. Immtech is in discussions with potential joint venture partners regarding co-development of Immtech's proprietary compounds. The Company's organizational structure will continue to evolve so that we can be best positioned to succeed in this dynamic environment." said Eric L. Sorkin, Immtech's Chairman and Chief Executive Officer.

In March 2009, Immtech announced an investment in Gold Avenue Ltd., a privately-held Hong Kong company with interests in tin production in China. The Company recently signed a memorandum of understanding to explore development of strategic business alliances with Beijing Pharmaceutical Group, and it has also obtained various letters of interest from pharmaceutical companies pertaining to the Company's HCV program.

About Immtech Pharmaceuticals, Inc.

Immtech Pharmaceuticals, Inc. and subsidiaries (a development stage enterprise) is focused on global development in the healthcare sector and opportunities in China. Immtech aims to apply its established expertise and assets in both new drug development and enhanced healthcare-related services, including research and content distribution for developed and developing countries. For additional information, please visit the Company's website at http://www.immtechpharma.com.

"Safe Harbor" Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech Pharmaceuticals, Inc.'s business which are not historical facts, are "forward-looking statements" that involve risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the headings "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" in Immtech's annual report on Form 10-K for the year ended March 31, 2008 filed on June 18, 2008, and in its other SEC filings and include, but are not limited to: (i) conditions in the credit markets and the general economy; (ii) Immtech's ability to obtain additional funds; (iii) Immtech's ability to manage its remaining resources; (iv) Immtech's ability to continue as a going concern; (v) Immtech's ability to retain key personnel; (vi) the ability of Immtech's scientists and collaborators to discover new compounds; (vii) the availability of additional research grants; (viii) Immtech's ability to obtain regulatory approval of its drug candidates; (ix) the success of Immtech's clinical trials; (x) dependence upon and contractual relationship with partners; (xi) Immtech's ability to protect its intellectual property; and (xii) competition and alternative technologies.

In addition, Immtech does not undertake any obligation, and specifically disclaims any obligation to publicly update or revise forward-looking statements to reflect future events, information or circumstances that arise after the date of this release.


'/>"/>
SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Immtech Receives Listing Determination Letter
2. Immtech To Reschedule Quarterly Conference Call
3. Immtech Reports Fiscal Third Quarter 2009 Results
4. Immtech Announces Sale of Property Subsidiary in China
5. Immtech Receives Listing Notice From NYSE Alternext US
6. Immtech Reports Fiscal Second Quarter 2009 Results
7. Immtech Investor Conference Call Scheduled for June 25, 2008
8. Immtech Reports Fiscal Year End 2008 Results
9. Immtech Announces Results From Hepatitis C Discovery Program
10. Immtech Announces Update on Business Operations
11. Immtech Investor Conference Call Scheduled for February 22, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... ... An inventor from Cana, Va., wanted to fulfill the need for a device ... The patent-pending SAFETY STRAP FOR AMPUTEES improves accessibility. It eliminates discrimination. It is also ... a matter of minutes, or even seconds. The SAFETY STRAP FOR AMPUTEES is a ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Pennsylvania Athletic Trainers’ Society ... the summer of 2016. The program was made possible by a Pennsylvania Department ... of Health and Human Services Administration. The broadcast, Use Your Head: Properly ...
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc , ... Processing–Enabled and Conventional Data Capture Methods for Input to Electronic Health Records: A ... Results of the comparative usability study demonstrate that a dictation-based method (“NLP Entry”) ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... 2016 , ... STATEN ISLAND, N.Y., Nov. 24, 2016 — ... highest standards of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) services ... Daniel Messina. , Among the recognitions, the American College of Surgeons' (ACS) named ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... STOUGHTON, Mass. , Dec. 9, 2016 ... device and supply chain solutions to alternate site health ... merger with First Choice Medical Supply ("First Choice"), a ... products servicing the skilled nursing and home health segments. ... MSD family. This compelling transaction will ...
(Date:12/9/2016)... 2016 Research and Markets has announced ... to 2021" report to their offering. ... Market growth can ... in the pharmaceutical and biotechnology industry and technological advancements like ... Emerging markets and growing research activities in toxicology and stem ...
(Date:12/9/2016)... Research and Markets has announced the addition of the "Global ... ... market to grow at a CAGR of 6.83% during the period ... growth prospects of the global travel vaccines market for 2016-2020. To ... the sales of various vaccines administered to actively immunize meningococcal disease, ...
Breaking Medicine Technology: